Treatment of open angle glaucoma or ocular hypertension with preservative‐free tafluprost/timolol fixed dose combination in a real‐world clinical practice setting: a cross‐country subanalysis

Abstract

AbstractPurposeThe VISIONARY study assessed, in a real‐world clinical practice setting, the efficacy of preservative‐free tafluprost/timolol fixed‐dose combination (PF tafluprost/timolol FC) in adults with open‐angle glaucoma (OAG) or ocular hypertension (OHT) who did not achieve an adequate response to initial prostaglandin (PGA) or beta‐blocker (BB) monotherapy. This analysis examined the results reported by 7 countries (Italy, Hungary, Spain, Russia, UK, Latvia and Norway) enrolling >10 patients.MethodsBaseline measurements of IOP were recorded in adults (≥18 years) receiving topical PGA or BB monotherapy for OAG/OHT and treatment was switched to PF tafluprost/timolol FC. IOP was measured at Weeks 4, 12 and 24 during routine ophthalmology visits. The primary endpoint was mean absolute change in IOP from baseline at Month 6, post‐treatment switch. Secondary endpoints included adverse event (AE) reporting and tolerability.ResultsChange in the mean IOP from baseline at Month 6 was 5.7 mmHg (24.9% reduction) for the overall population. Percentage reduction in IOP for the individual countries ranged from 22.3–31.8%. A statistically significant reduction in IOP from baseline was observed at all time points among patients from all countries. The highest percentage reduction in IOP was seen in Latvia at Month 6 (31.8%). Patient‐assessed tolerability was very good/good in 94% of patients. Most reported AEs were mild/moderate in severity and had resolved by the end of the study period.ConclusionsIn a real‐world clinical practice setting, PF tafluprost/timolol FC provided effective and well‐tolerated treatment for OAG/OHT patients insufficiently controlled on BB or PGA monotherapy. Results were consistent across all countries included in the study.BibliographyOddone F, et al. Treatment of Open‐Angle Glaucoma and Ocular Hypertension with Preservative‐Free Tafluprost/Timolol Fixed‐Dose Combination Therapy: The VISIONARY Study. Adv Ther.2020;37(4):1436‐51